(Q50794802)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

main subject

phase I clinical trial

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tanja Lövgren

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Isabel Poschke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lars Adamson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Maria Nyström

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Emilia Andersson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Johan Hansson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Roger Tell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Rolf Kiessling

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

4 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1061-1071

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24993563%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-014-1575-2

21 March 2020

exact match

0 references

cites work

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1575-2